Page 58 - Q. Neuroscience

[Q. Neuroscience-34]

Development of levodopa induced dyskinesia mouse model

combining with mutant α-synuclein and MPTP

Eunji Namgung¹˙²˙³˙#, Soo jeong Kim¹˙³˙#, Min Jeong Ryu¹, Yunseon Jang¹˙²˙³, Min joung Lee¹˙²˙³, Xianshu Ju¹˙²˙³,
Jianchen Cui¹˙²˙³, Yu Lim Lee¹˙²˙³, Jiebo Zhu¹˙²˙³, Dahyun Go¹˙²˙³, Chang Jun Seo¹˙²˙³, Woosuk Chung¹˙²˙³,

Gi Ryang Kweon¹˙²˙³, Jun Young Heo¹˙²˙³˙*

¹Biochemistry, Chungnam National University School of Medicine, Daejeon 35015, South Korea, ²Medical Science,
Chungnam National University School of Medicine, Daejeon 35015, South Korea, ³nfection Control Convergence

Research Center, Chungnam National University School of Medicine, Daejeon 35015, South Korea, ⁴Anesthesiology
and Pain medicine, Chungnam National University Hospital, Daejeon 35015, South Korea

Levodopa (LD) is the first line therapy for Parkinson's disease (PD), which improves PD behavioral symptoms.

However, long terms (10 years) treatment of LD could occur dyskinetic movement over 80% of PD patients. Levodopa
induced dyskinesia (LID) can be treated with DBS (deep brain stimulation), but there is a risk of bleeding, infection

accompany with surgery, so the development of a medicine that alleviates LID symptom is essential. For pre-clinical
trial, the development of animal model which recapitulates LID patient symptoms should be preceded, at present

the predominantly used model of LID is neurotoxin induced PD animal model. To develop the recapitulate the LID
patient symptoms, we generate the LID animal model combine with α-synuclein(α-syn) and MPTP. Here, we

performed stereotaxic surgery with α-syn A53T virus in the SN region, and administrated MPTP after two weeks
later and then treated LD twice a day for a week to induce LID. We established a new combined LID animal model

by confirming more severe abnormal involuntary movement scale (AIMS) than only α-syn or MPTP treated model.
This result will provide an important experimental platform that serves for clinical trial as animal models that most

closely recapitulate patients with LID symptoms.